<qa>  What is the name of the PATIENTS WITH HIGHRISK OR RECURRENTTHERAPEUTIC ALLOGENEIC LYMPHOCYTES AND ALDESLEUKIN IN TREATING PATIENTS WITH HIGH-RISK OR RECURRENT MYELOID LEUKEMIA AFTER UNDERGOING DONOR STEM CELL TRANSPLANT: 